Approval · Notice of Compliance 24850 · 2020
ADDERALL XR: Notice of Compliance 24850
Issued December 21, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24850
- Date
- December 21, 2020
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Update the product monograph to the 2016 format. merger - buyout
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADDERALL XR | 02248808 | Marketed |
| ADDERALL XR | 02248809 | Marketed |
| ADDERALL XR | 02248810 | Marketed |
| ADDERALL XR | 02248811 | Marketed |
| ADDERALL XR | 02248812 | Marketed |
| ADDERALL XR | 02248813 | Marketed |
Medicinal ingredients
- AMPHETAMINE ASPARTATE 1.25 MG per CAP
- AMPHETAMINE SULFATE 1.25 MG per CAP
- DEXTROAMPHETAMINE SACCHARATE 1.25 MG per CAP
- DEXTROAMPHETAMINE SULFATE 1.25 MG per CAP
- AMPHETAMINE ASPARTATE 2.5 MG per CAP
- AMPHETAMINE SULFATE 2.5 MG per CAP
- DEXTROAMPHETAMINE SACCHARATE 2.5 MG per CAP
- DEXTROAMPHETAMINE SULFATE 2.5 MG per CAP
- AMPHETAMINE ASPARTATE 3.75 MG per CAP
- AMPHETAMINE SULFATE 3.75 MG per CAP
- DEXTROAMPHETAMINE SACCHARATE 3.75 MG per CAP
- DEXTROAMPHETAMINE SULFATE 3.75 MG per CAP
- AMPHETAMINE ASPARTATE 5 MG per CAP
- AMPHETAMINE SULFATE 5 MG per CAP
- DEXTROAMPHETAMINE SACCHARATE 5 MG per CAP
- DEXTROAMPHETAMINE SULFATE 5 MG per CAP
- AMPHETAMINE ASPARTATE 6.25 MG per CAP
- AMPHETAMINE SULFATE 6.25 MG per CAP
- DEXTROAMPHETAMINE SACCHARATE 6.25 MG per CAP
- DEXTROAMPHETAMINE SULFATE 6.25 MG per CAP
- AMPHETAMINE ASPARTATE 7.5 MG per CAP
- AMPHETAMINE SULFATE 7.5 MG per CAP
- DEXTROAMPHETAMINE SACCHARATE 7.5 MG per CAP
- DEXTROAMPHETAMINE SULFATE 7.5 MG per CAP